Rallybio Corporation (RLYB)
RLYBNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$15.70
+0.0400 (+0.26%) today
At the close, Nov 10, 4:00 PM ET. After hours $15.35 -2.60%
- Market cap
- $84.85m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $15.32 to $15.76
- 52-week range
- $3.67 to $17.57
- Average volume
- 18.6k
- Previous close
- $15.66
Earnings
Next report
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $222.0k | $212.0k | – | – |
| Gross profit | $222.0k | $212.0k | – | – |
| Operating income | -$6.41m | -$8.73m | -$5.65m | -$3.42m |
| Net income | -$5.85m | -$8.28m | $43.66m | -$2.73m |
News
8 latest- Rallybio Corporation Postpones Merger Closing Originally Scheduled for November 6, 2026Fintel · 4 days ago
- Rallybio Stockholders Approve Avenzo Merger, Name Change and Reverse SplitMarketBeat · 6 days ago
- Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch RTTNews · Jun 1, 2026
- Rallybio (RLYB) Price Target Increased by 700.00% to 8.16Fintel · Feb 24, 2026
- Weekly Buzz: NRXP Sets The Path For NRX-100's NDA; IRON Gets FDA's CRL; TOVX Licenses SYN-020 RTTNews · Feb 20, 2026
- Rallybio Reports Positive Data For RLYB116 Phase 1 Study RTTNews · Feb 17, 2026
- Rallybio To Implement 1 For 8 Reverse Stock Split To Regain Nasdaq Compliance;Stock Down RTTNews · Feb 4, 2026
- After-Hours Biotech Watch: IFRX, ABCL, RLYB Among Notable Risers RTTNews · Nov 9, 2025
The company
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of complement dysregulation and hematology. The Company's lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Rallybio is headquartered in New Haven, Connecticut.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- rallybio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.